Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our (LP Info Research) latest study, the global Paroxysmal Nocturnal Hemoglobinuria Drug market size was valued at US$ 3130.4 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Paroxysmal Nocturnal Hemoglobinuria Drug is forecast to a readjusted size of US$ 7589.1 million by 2029 with a CAGR of 13.5% during review period.
The research report highlights the growth potential of the global Paroxysmal Nocturnal Hemoglobinuria Drug market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Paroxysmal Nocturnal Hemoglobinuria Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Paroxysmal Nocturnal Hemoglobinuria Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Key Features:
The report on Paroxysmal Nocturnal Hemoglobinuria Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Paroxysmal Nocturnal Hemoglobinuria Drug market. It may include historical data, market segmentation by Type (e.g., Eculizumab, Ravulizumab), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Paroxysmal Nocturnal Hemoglobinuria Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Paroxysmal Nocturnal Hemoglobinuria Drug industry. This include advancements in Paroxysmal Nocturnal Hemoglobinuria Drug technology, Paroxysmal Nocturnal Hemoglobinuria Drug new entrants, Paroxysmal Nocturnal Hemoglobinuria Drug new investment, and other innovations that are shaping the future of Paroxysmal Nocturnal Hemoglobinuria Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Paroxysmal Nocturnal Hemoglobinuria Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Paroxysmal Nocturnal Hemoglobinuria Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Paroxysmal Nocturnal Hemoglobinuria Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Paroxysmal Nocturnal Hemoglobinuria Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Market Segmentation:
Paroxysmal Nocturnal Hemoglobinuria Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria Drug market?
What factors are driving Paroxysmal Nocturnal Hemoglobinuria Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paroxysmal Nocturnal Hemoglobinuria Drug market opportunities vary by end market size?
How does Paroxysmal Nocturnal Hemoglobinuria Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
According to our (LP Info Research) latest study, the global Paroxysmal Nocturnal Hemoglobinuria Drug market size was valued at US$ 3130.4 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Paroxysmal Nocturnal Hemoglobinuria Drug is forecast to a readjusted size of US$ 7589.1 million by 2029 with a CAGR of 13.5% during review period.
The research report highlights the growth potential of the global Paroxysmal Nocturnal Hemoglobinuria Drug market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Paroxysmal Nocturnal Hemoglobinuria Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Paroxysmal Nocturnal Hemoglobinuria Drug. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Key Features:
The report on Paroxysmal Nocturnal Hemoglobinuria Drug market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Paroxysmal Nocturnal Hemoglobinuria Drug market. It may include historical data, market segmentation by Type (e.g., Eculizumab, Ravulizumab), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Paroxysmal Nocturnal Hemoglobinuria Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Paroxysmal Nocturnal Hemoglobinuria Drug industry. This include advancements in Paroxysmal Nocturnal Hemoglobinuria Drug technology, Paroxysmal Nocturnal Hemoglobinuria Drug new entrants, Paroxysmal Nocturnal Hemoglobinuria Drug new investment, and other innovations that are shaping the future of Paroxysmal Nocturnal Hemoglobinuria Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Paroxysmal Nocturnal Hemoglobinuria Drug market. It includes factors influencing customer ' purchasing decisions, preferences for Paroxysmal Nocturnal Hemoglobinuria Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Paroxysmal Nocturnal Hemoglobinuria Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Paroxysmal Nocturnal Hemoglobinuria Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Paroxysmal Nocturnal Hemoglobinuria Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Paroxysmal Nocturnal Hemoglobinuria Drug market.
Market Segmentation:
Paroxysmal Nocturnal Hemoglobinuria Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Eculizumab
- Ravulizumab
- Others
- Clinic
- Hospital
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Apellis Pharmaceuticals
- Alexion Pharmaceuticals Inc
- Akari Therapeutics Plc
- CinnaGen Co
- Ra Pharmaceuticals Inc
- Amgen Inc
- Achillion Pharmaceuticals Inc
- Alnylam Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Regeneron Pharmaceuticals Inc
- BIOCAD
- Samsung Bioepis
- Amyndas Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- LGM Pharma.
- Lannett
- NorthStar Rx LLC
- Abbott
- Par Pharmaceutical
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria Drug market?
What factors are driving Paroxysmal Nocturnal Hemoglobinuria Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paroxysmal Nocturnal Hemoglobinuria Drug market opportunities vary by end market size?
How does Paroxysmal Nocturnal Hemoglobinuria Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria Drug by Country/Region, 2018, 2022 & 2029
2.2 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Type
2.2.1 Eculizumab
2.2.2 Ravulizumab
2.2.3 Others
2.3 Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Type (2018-2023)
2.4 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
2.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Application (2018-2023)
3 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY COMPANY
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Breakdown Data by Company
3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Company (2018-2023)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company (2018-2023)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Company (2018-2023)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company (2018-2023)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Company
3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Product Location Distribution
3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY GEOGRAPHIC REGION
4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
4.4 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
4.5 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
5 AMERICAS
5.1 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country
5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
5.2 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
5.3 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018-2023)
6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2018-2023)
6.2 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
6.3 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug by Country
7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug by Country
8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors
11.3 Paroxysmal Nocturnal Hemoglobinuria Drug Customer
12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY GEOGRAPHIC REGION
12.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Region
12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Region (2024-2029)
12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Type
12.7 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Apellis Pharmaceuticals
13.1.1 Apellis Pharmaceuticals Company Information
13.1.2 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Apellis Pharmaceuticals Main Business Overview
13.1.5 Apellis Pharmaceuticals Latest Developments
13.2 Alexion Pharmaceuticals Inc
13.2.1 Alexion Pharmaceuticals Inc Company Information
13.2.2 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Alexion Pharmaceuticals Inc Main Business Overview
13.2.5 Alexion Pharmaceuticals Inc Latest Developments
13.3 Akari Therapeutics Plc
13.3.1 Akari Therapeutics Plc Company Information
13.3.2 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Akari Therapeutics Plc Main Business Overview
13.3.5 Akari Therapeutics Plc Latest Developments
13.4 CinnaGen Co
13.4.1 CinnaGen Co Company Information
13.4.2 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 CinnaGen Co Main Business Overview
13.4.5 CinnaGen Co Latest Developments
13.5 Ra Pharmaceuticals Inc
13.5.1 Ra Pharmaceuticals Inc Company Information
13.5.2 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ra Pharmaceuticals Inc Main Business Overview
13.5.5 Ra Pharmaceuticals Inc Latest Developments
13.6 Amgen Inc
13.6.1 Amgen Inc Company Information
13.6.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc Main Business Overview
13.6.5 Amgen Inc Latest Developments
13.7 Achillion Pharmaceuticals Inc
13.7.1 Achillion Pharmaceuticals Inc Company Information
13.7.2 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Achillion Pharmaceuticals Inc Main Business Overview
13.7.5 Achillion Pharmaceuticals Inc Latest Developments
13.8 Alnylam Pharmaceuticals Inc
13.8.1 Alnylam Pharmaceuticals Inc Company Information
13.8.2 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Alnylam Pharmaceuticals Inc Main Business Overview
13.8.5 Alnylam Pharmaceuticals Inc Latest Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 F. Hoffmann-La Roche Ltd Company Information
13.9.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.9.5 F. Hoffmann-La Roche Ltd Latest Developments
13.10 Novartis AG
13.10.1 Novartis AG Company Information
13.10.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Novartis AG Main Business Overview
13.10.5 Novartis AG Latest Developments
13.11 Regeneron Pharmaceuticals Inc
13.11.1 Regeneron Pharmaceuticals Inc Company Information
13.11.2 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.11.5 Regeneron Pharmaceuticals Inc Latest Developments
13.12 BIOCAD
13.12.1 BIOCAD Company Information
13.12.2 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 BIOCAD Main Business Overview
13.12.5 BIOCAD Latest Developments
13.13 Samsung Bioepis
13.13.1 Samsung Bioepis Company Information
13.13.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Samsung Bioepis Main Business Overview
13.13.5 Samsung Bioepis Latest Developments
13.14 Amyndas Pharmaceuticals
13.14.1 Amyndas Pharmaceuticals Company Information
13.14.2 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Amyndas Pharmaceuticals Main Business Overview
13.14.5 Amyndas Pharmaceuticals Latest Developments
13.15 Teva Pharmaceutical Industries Ltd.
13.15.1 Teva Pharmaceutical Industries Ltd. Company Information
13.15.2 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
13.15.5 Teva Pharmaceutical Industries Ltd. Latest Developments
13.16 LGM Pharma.
13.16.1 LGM Pharma. Company Information
13.16.2 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 LGM Pharma. Main Business Overview
13.16.5 LGM Pharma. Latest Developments
13.17 Lannett
13.17.1 Lannett Company Information
13.17.2 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Lannett Main Business Overview
13.17.5 Lannett Latest Developments
13.18 NorthStar Rx LLC
13.18.1 NorthStar Rx LLC Company Information
13.18.2 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 NorthStar Rx LLC Main Business Overview
13.18.5 NorthStar Rx LLC Latest Developments
13.19 Abbott
13.19.1 Abbott Company Information
13.19.2 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Abbott Main Business Overview
13.19.5 Abbott Latest Developments
13.20 Par Pharmaceutical
13.20.1 Par Pharmaceutical Company Information
13.20.2 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Par Pharmaceutical Main Business Overview
13.20.5 Par Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria Drug by Country/Region, 2018, 2022 & 2029
2.2 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Type
2.2.1 Eculizumab
2.2.2 Ravulizumab
2.2.3 Others
2.3 Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Type (2018-2023)
2.4 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
2.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Application (2018-2023)
3 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY COMPANY
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Breakdown Data by Company
3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Company (2018-2023)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company (2018-2023)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Company (2018-2023)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company (2018-2023)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Company
3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Product Location Distribution
3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY GEOGRAPHIC REGION
4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
4.4 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
4.5 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth
5 AMERICAS
5.1 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country
5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
5.2 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
5.3 Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018-2023)
6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2018-2023)
6.2 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
6.3 APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug by Country
7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug by Country
8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type
8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors
11.3 Paroxysmal Nocturnal Hemoglobinuria Drug Customer
12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG BY GEOGRAPHIC REGION
12.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Region
12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Region (2024-2029)
12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Type
12.7 Global Paroxysmal Nocturnal Hemoglobinuria Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Apellis Pharmaceuticals
13.1.1 Apellis Pharmaceuticals Company Information
13.1.2 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Apellis Pharmaceuticals Main Business Overview
13.1.5 Apellis Pharmaceuticals Latest Developments
13.2 Alexion Pharmaceuticals Inc
13.2.1 Alexion Pharmaceuticals Inc Company Information
13.2.2 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Alexion Pharmaceuticals Inc Main Business Overview
13.2.5 Alexion Pharmaceuticals Inc Latest Developments
13.3 Akari Therapeutics Plc
13.3.1 Akari Therapeutics Plc Company Information
13.3.2 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Akari Therapeutics Plc Main Business Overview
13.3.5 Akari Therapeutics Plc Latest Developments
13.4 CinnaGen Co
13.4.1 CinnaGen Co Company Information
13.4.2 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 CinnaGen Co Main Business Overview
13.4.5 CinnaGen Co Latest Developments
13.5 Ra Pharmaceuticals Inc
13.5.1 Ra Pharmaceuticals Inc Company Information
13.5.2 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Ra Pharmaceuticals Inc Main Business Overview
13.5.5 Ra Pharmaceuticals Inc Latest Developments
13.6 Amgen Inc
13.6.1 Amgen Inc Company Information
13.6.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc Main Business Overview
13.6.5 Amgen Inc Latest Developments
13.7 Achillion Pharmaceuticals Inc
13.7.1 Achillion Pharmaceuticals Inc Company Information
13.7.2 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Achillion Pharmaceuticals Inc Main Business Overview
13.7.5 Achillion Pharmaceuticals Inc Latest Developments
13.8 Alnylam Pharmaceuticals Inc
13.8.1 Alnylam Pharmaceuticals Inc Company Information
13.8.2 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Alnylam Pharmaceuticals Inc Main Business Overview
13.8.5 Alnylam Pharmaceuticals Inc Latest Developments
13.9 F. Hoffmann-La Roche Ltd
13.9.1 F. Hoffmann-La Roche Ltd Company Information
13.9.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.9.5 F. Hoffmann-La Roche Ltd Latest Developments
13.10 Novartis AG
13.10.1 Novartis AG Company Information
13.10.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Novartis AG Main Business Overview
13.10.5 Novartis AG Latest Developments
13.11 Regeneron Pharmaceuticals Inc
13.11.1 Regeneron Pharmaceuticals Inc Company Information
13.11.2 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.11.5 Regeneron Pharmaceuticals Inc Latest Developments
13.12 BIOCAD
13.12.1 BIOCAD Company Information
13.12.2 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 BIOCAD Main Business Overview
13.12.5 BIOCAD Latest Developments
13.13 Samsung Bioepis
13.13.1 Samsung Bioepis Company Information
13.13.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Samsung Bioepis Main Business Overview
13.13.5 Samsung Bioepis Latest Developments
13.14 Amyndas Pharmaceuticals
13.14.1 Amyndas Pharmaceuticals Company Information
13.14.2 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Amyndas Pharmaceuticals Main Business Overview
13.14.5 Amyndas Pharmaceuticals Latest Developments
13.15 Teva Pharmaceutical Industries Ltd.
13.15.1 Teva Pharmaceutical Industries Ltd. Company Information
13.15.2 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
13.15.5 Teva Pharmaceutical Industries Ltd. Latest Developments
13.16 LGM Pharma.
13.16.1 LGM Pharma. Company Information
13.16.2 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 LGM Pharma. Main Business Overview
13.16.5 LGM Pharma. Latest Developments
13.17 Lannett
13.17.1 Lannett Company Information
13.17.2 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Lannett Main Business Overview
13.17.5 Lannett Latest Developments
13.18 NorthStar Rx LLC
13.18.1 NorthStar Rx LLC Company Information
13.18.2 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 NorthStar Rx LLC Main Business Overview
13.18.5 NorthStar Rx LLC Latest Developments
13.19 Abbott
13.19.1 Abbott Company Information
13.19.2 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Abbott Main Business Overview
13.19.5 Abbott Latest Developments
13.20 Par Pharmaceutical
13.20.1 Par Pharmaceutical Company Information
13.20.2 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
13.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Par Pharmaceutical Main Business Overview
13.20.5 Par Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Eculizumab
Table 4. Major Players of Ravulizumab
Table 5. Major Players of Others
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2018-2023) & ($ million)
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2023)
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2018-2023)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2018-2023)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Company (2018-2023) & (K Units)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company (2018-2023)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company (2018-2023)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Producing Area Distribution and Sales Area
Table 22. Players Paroxysmal Nocturnal Hemoglobinuria Drug Products Offered
Table 23. Paroxysmal Nocturnal Hemoglobinuria Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Geographic Region (2018-2023)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country/Region (2018-2023)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
Table 35. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
Table 36. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
Table 38. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 39. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 40. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018-2023) & (K Units)
Table 41. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2018-2023)
Table 42. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2018-2023)
Table 44. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 45. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
Table 47. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
Table 48. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria Drug
Table 59. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria Drug
Table 60. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria Drug
Table 61. Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Paroxysmal Nocturnal Hemoglobinuria Drug Distributors List
Table 64. Paroxysmal Nocturnal Hemoglobinuria Drug Customer List
Table 65. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Apellis Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 81. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Apellis Pharmaceuticals Main Business
Table 83. Apellis Pharmaceuticals Latest Developments
Table 84. Alexion Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 86. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Alexion Pharmaceuticals Inc Main Business
Table 88. Alexion Pharmaceuticals Inc Latest Developments
Table 89. Akari Therapeutics Plc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 91. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Akari Therapeutics Plc Main Business
Table 93. Akari Therapeutics Plc Latest Developments
Table 94. CinnaGen Co Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 96. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. CinnaGen Co Main Business
Table 98. CinnaGen Co Latest Developments
Table 99. Ra Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 101. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Ra Pharmaceuticals Inc Main Business
Table 103. Ra Pharmaceuticals Inc Latest Developments
Table 104. Amgen Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 106. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Amgen Inc Main Business
Table 108. Amgen Inc Latest Developments
Table 109. Achillion Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 111. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Achillion Pharmaceuticals Inc Main Business
Table 113. Achillion Pharmaceuticals Inc Latest Developments
Table 114. Alnylam Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 116. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Alnylam Pharmaceuticals Inc Main Business
Table 118. Alnylam Pharmaceuticals Inc Latest Developments
Table 119. F. Hoffmann-La Roche Ltd Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 121. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. F. Hoffmann-La Roche Ltd Main Business
Table 123. F. Hoffmann-La Roche Ltd Latest Developments
Table 124. Novartis AG Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 126. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Novartis AG Main Business
Table 128. Novartis AG Latest Developments
Table 129. Regeneron Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 130. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 131. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Regeneron Pharmaceuticals Inc Main Business
Table 133. Regeneron Pharmaceuticals Inc Latest Developments
Table 134. BIOCAD Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 135. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 136. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. BIOCAD Main Business
Table 138. BIOCAD Latest Developments
Table 139. Samsung Bioepis Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 140. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 141. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Samsung Bioepis Main Business
Table 143. Samsung Bioepis Latest Developments
Table 144. Amyndas Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 145. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 146. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Amyndas Pharmaceuticals Main Business
Table 148. Amyndas Pharmaceuticals Latest Developments
Table 149. Teva Pharmaceutical Industries Ltd. Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 150. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 151. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Teva Pharmaceutical Industries Ltd. Main Business
Table 153. Teva Pharmaceutical Industries Ltd. Latest Developments
Table 154. LGM Pharma. Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 155. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 156. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 157. LGM Pharma. Main Business
Table 158. LGM Pharma. Latest Developments
Table 159. Lannett Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 160. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 161. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 162. Lannett Main Business
Table 163. Lannett Latest Developments
Table 164. NorthStar Rx LLC Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 165. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 166. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 167. NorthStar Rx LLC Main Business
Table 168. NorthStar Rx LLC Latest Developments
Table 169. Abbott Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 170. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 171. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 172. Abbott Main Business
Table 173. Abbott Latest Developments
Table 174. Par Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 175. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 176. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 177. Par Pharmaceutical Main Business
Table 178. Par Pharmaceutical Latest Developments
Table 1. Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Paroxysmal Nocturnal Hemoglobinuria Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Eculizumab
Table 4. Major Players of Ravulizumab
Table 5. Major Players of Others
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2018-2023) & ($ million)
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2023)
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2018-2023)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2018-2023)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Company (2018-2023) & (K Units)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company (2018-2023)
Table 18. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company (2018-2023)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Producing Area Distribution and Sales Area
Table 22. Players Paroxysmal Nocturnal Hemoglobinuria Drug Products Offered
Table 23. Paroxysmal Nocturnal Hemoglobinuria Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Geographic Region (2018-2023)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country/Region (2018-2023)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
Table 35. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
Table 36. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
Table 38. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 39. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 40. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018-2023) & (K Units)
Table 41. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region (2018-2023)
Table 42. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Region (2018-2023)
Table 44. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 45. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 46. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
Table 47. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
Table 48. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
Table 50. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 51. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria Drug
Table 59. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria Drug
Table 60. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria Drug
Table 61. Paroxysmal Nocturnal Hemoglobinuria Drug Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Paroxysmal Nocturnal Hemoglobinuria Drug Distributors List
Table 64. Paroxysmal Nocturnal Hemoglobinuria Drug Customer List
Table 65. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Apellis Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 81. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Apellis Pharmaceuticals Main Business
Table 83. Apellis Pharmaceuticals Latest Developments
Table 84. Alexion Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 86. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Alexion Pharmaceuticals Inc Main Business
Table 88. Alexion Pharmaceuticals Inc Latest Developments
Table 89. Akari Therapeutics Plc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 91. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Akari Therapeutics Plc Main Business
Table 93. Akari Therapeutics Plc Latest Developments
Table 94. CinnaGen Co Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 96. CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. CinnaGen Co Main Business
Table 98. CinnaGen Co Latest Developments
Table 99. Ra Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 101. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Ra Pharmaceuticals Inc Main Business
Table 103. Ra Pharmaceuticals Inc Latest Developments
Table 104. Amgen Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 106. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Amgen Inc Main Business
Table 108. Amgen Inc Latest Developments
Table 109. Achillion Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 111. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Achillion Pharmaceuticals Inc Main Business
Table 113. Achillion Pharmaceuticals Inc Latest Developments
Table 114. Alnylam Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 116. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Alnylam Pharmaceuticals Inc Main Business
Table 118. Alnylam Pharmaceuticals Inc Latest Developments
Table 119. F. Hoffmann-La Roche Ltd Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 121. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. F. Hoffmann-La Roche Ltd Main Business
Table 123. F. Hoffmann-La Roche Ltd Latest Developments
Table 124. Novartis AG Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 125. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 126. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Novartis AG Main Business
Table 128. Novartis AG Latest Developments
Table 129. Regeneron Pharmaceuticals Inc Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 130. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 131. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Regeneron Pharmaceuticals Inc Main Business
Table 133. Regeneron Pharmaceuticals Inc Latest Developments
Table 134. BIOCAD Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 135. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 136. BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. BIOCAD Main Business
Table 138. BIOCAD Latest Developments
Table 139. Samsung Bioepis Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 140. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 141. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Samsung Bioepis Main Business
Table 143. Samsung Bioepis Latest Developments
Table 144. Amyndas Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 145. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 146. Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Amyndas Pharmaceuticals Main Business
Table 148. Amyndas Pharmaceuticals Latest Developments
Table 149. Teva Pharmaceutical Industries Ltd. Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 150. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 151. Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Teva Pharmaceutical Industries Ltd. Main Business
Table 153. Teva Pharmaceutical Industries Ltd. Latest Developments
Table 154. LGM Pharma. Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 155. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 156. LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 157. LGM Pharma. Main Business
Table 158. LGM Pharma. Latest Developments
Table 159. Lannett Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 160. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 161. Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 162. Lannett Main Business
Table 163. Lannett Latest Developments
Table 164. NorthStar Rx LLC Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 165. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 166. NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 167. NorthStar Rx LLC Main Business
Table 168. NorthStar Rx LLC Latest Developments
Table 169. Abbott Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 170. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 171. Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 172. Abbott Main Business
Table 173. Abbott Latest Developments
Table 174. Par Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria Drug Manufacturing Base, Sales Area and Its Competitors
Table 175. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolios and Specifications
Table 176. Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 177. Par Pharmaceutical Main Business
Table 178. Par Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 2. Paroxysmal Nocturnal Hemoglobinuria Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Eculizumab
Figure 10. Product Picture of Ravulizumab
Figure 11. Product Picture of Others
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type in 2022
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2023)
Figure 14. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Clinic
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Clinic (2018-2023) & (K Units)
Figure 16. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Hospital
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Hospital (2018-2023) & (K Units)
Figure 18. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Others
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Others (2018-2023) & (K Units)
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2022)
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application in 2022
Figure 22. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market by Company in 2022 (K Units)
Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company in 2022
Figure 24. Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company in 2022
Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 29. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 30. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 31. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 36. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
Figure 37. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
Figure 38. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 40. United States Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region in 2022
Figure 45. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Regions in 2022
Figure 46. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 47. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 48. China Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
Figure 57. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 58. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 59. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 68. Egypt Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug in 2022
Figure 74. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 75. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 76. Channels of Distribution
Figure 77. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Forecast by Region (2024-2029)
Figure 78. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 2. Paroxysmal Nocturnal Hemoglobinuria Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Eculizumab
Figure 10. Product Picture of Ravulizumab
Figure 11. Product Picture of Others
Figure 12. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type in 2022
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2023)
Figure 14. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Clinic
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Clinic (2018-2023) & (K Units)
Figure 16. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Hospital
Figure 17. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Hospital (2018-2023) & (K Units)
Figure 18. Paroxysmal Nocturnal Hemoglobinuria Drug Consumed in Others
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Others (2018-2023) & (K Units)
Figure 20. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2022)
Figure 21. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application in 2022
Figure 22. Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market by Company in 2022 (K Units)
Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Company in 2022
Figure 24. Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Company in 2022
Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 29. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 30. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 31. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 32. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 33. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2023 ($ Millions)
Figure 36. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
Figure 37. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
Figure 38. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 40. United States Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region in 2022
Figure 45. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Regions in 2022
Figure 46. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 47. APAC Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 48. China Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
Figure 57. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 58. Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 59. Germany Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2023)
Figure 68. Egypt Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug in 2022
Figure 74. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 75. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria Drug
Figure 76. Channels of Distribution
Figure 77. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Forecast by Region (2024-2029)
Figure 78. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share Forecast by Application (2024-2029)
